Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: Meta-analysis of clinical trials

Fabrizio Fabrizi, Gareth Dulai, Vivek Dixit, Suphamai Bunnapradist, Paul Martin

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background. Numerous reports have appeared on lamivudine use for the treatment of hepatitis B virus (HBV) infection after renal transplantation (RT). However, the efficacy and safety of lamivudine after RT remain unclear. Methods. The authors evaluated the efficacy and safety of initial lamivudine monotherapy in RT recipients with hepatitis B by performing a systematic review of the literature with a meta-analysis of clinical trials. The primary outcomes were hepatitis B (HB) e antigen (Ag) and HBV-DNA clearance (as measures of efficacy); the secondary outcomes were biochemical response (as measures of efficacy), dropout rate, and lamivudine resistance (as measures of tolerability). The authors used the random effects model of DerSimonian and Laird, and outcomes were analyzed on an intent-to-treat basis. Results. The authors identified 14 clinical trials (184 patients); all of these were prospective cohort studies. The mean overall estimate for HBV-DNA and HBeAg clearance, alanine aminotransferase normalization, and lamivudine resistance was 91% (95% confidence interval [CI], 86%-96%), 27% (95% CI, 16%-39%), 81% (95% CI, 700%-92%), and 18% (95% CI, 10%-37%), respectively. HBeAg seroconversion rate was assessed in four (28%) trials and ranged between 0% and 46%. The P value was greater than 0.05 for our test of study homogeneity. There was no association between rate of patients who were male patients or had cirrhosis, race, age, lamivudine dose, and HBV-DNA or HBeAg clearance. Increased duration of lamivudine therapy was positively associated with frequency of HBeAg loss (r=0.51, P=0.039) and lamivudine resistance (r=0.620, P=0.019). Only 2 (14%) of 14 studies reported a dropout rate greater than 0%. Conclusions. Our meta-analysis showed that the majority of RT recipients with hepatitis B had high virologic and biochemical response with lamivudine. Tolerance to lamivudine was good. However, lamivudine resistance was frequent with prolonged therapy, potentially limiting its long-term efficacy after RT.

Original languageEnglish
Pages (from-to)859-864
Number of pages6
JournalTransplantation
Volume77
Issue number6
DOIs
StatePublished - Mar 27 2004
Externally publishedYes

Fingerprint

Lamivudine
Hepatitis B virus
Kidney Transplantation
Meta-Analysis
Liver Diseases
Clinical Trials
Hepatitis B e Antigens
Therapeutics
Confidence Intervals
Hepatitis B
DNA
Safety
Virus Diseases
Alanine Transaminase
Fibrosis
Cohort Studies
Prospective Studies

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation : Meta-analysis of clinical trials. / Fabrizi, Fabrizio; Dulai, Gareth; Dixit, Vivek; Bunnapradist, Suphamai; Martin, Paul.

In: Transplantation, Vol. 77, No. 6, 27.03.2004, p. 859-864.

Research output: Contribution to journalArticle

Fabrizi, Fabrizio ; Dulai, Gareth ; Dixit, Vivek ; Bunnapradist, Suphamai ; Martin, Paul. / Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation : Meta-analysis of clinical trials. In: Transplantation. 2004 ; Vol. 77, No. 6. pp. 859-864.
@article{a473afd6efc447aba384c2fdae116bca,
title = "Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: Meta-analysis of clinical trials",
abstract = "Background. Numerous reports have appeared on lamivudine use for the treatment of hepatitis B virus (HBV) infection after renal transplantation (RT). However, the efficacy and safety of lamivudine after RT remain unclear. Methods. The authors evaluated the efficacy and safety of initial lamivudine monotherapy in RT recipients with hepatitis B by performing a systematic review of the literature with a meta-analysis of clinical trials. The primary outcomes were hepatitis B (HB) e antigen (Ag) and HBV-DNA clearance (as measures of efficacy); the secondary outcomes were biochemical response (as measures of efficacy), dropout rate, and lamivudine resistance (as measures of tolerability). The authors used the random effects model of DerSimonian and Laird, and outcomes were analyzed on an intent-to-treat basis. Results. The authors identified 14 clinical trials (184 patients); all of these were prospective cohort studies. The mean overall estimate for HBV-DNA and HBeAg clearance, alanine aminotransferase normalization, and lamivudine resistance was 91{\%} (95{\%} confidence interval [CI], 86{\%}-96{\%}), 27{\%} (95{\%} CI, 16{\%}-39{\%}), 81{\%} (95{\%} CI, 700{\%}-92{\%}), and 18{\%} (95{\%} CI, 10{\%}-37{\%}), respectively. HBeAg seroconversion rate was assessed in four (28{\%}) trials and ranged between 0{\%} and 46{\%}. The P value was greater than 0.05 for our test of study homogeneity. There was no association between rate of patients who were male patients or had cirrhosis, race, age, lamivudine dose, and HBV-DNA or HBeAg clearance. Increased duration of lamivudine therapy was positively associated with frequency of HBeAg loss (r=0.51, P=0.039) and lamivudine resistance (r=0.620, P=0.019). Only 2 (14{\%}) of 14 studies reported a dropout rate greater than 0{\%}. Conclusions. Our meta-analysis showed that the majority of RT recipients with hepatitis B had high virologic and biochemical response with lamivudine. Tolerance to lamivudine was good. However, lamivudine resistance was frequent with prolonged therapy, potentially limiting its long-term efficacy after RT.",
author = "Fabrizio Fabrizi and Gareth Dulai and Vivek Dixit and Suphamai Bunnapradist and Paul Martin",
year = "2004",
month = "3",
day = "27",
doi = "10.1097/01.TP.0000116448.97841.6D",
language = "English",
volume = "77",
pages = "859--864",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation

T2 - Meta-analysis of clinical trials

AU - Fabrizi, Fabrizio

AU - Dulai, Gareth

AU - Dixit, Vivek

AU - Bunnapradist, Suphamai

AU - Martin, Paul

PY - 2004/3/27

Y1 - 2004/3/27

N2 - Background. Numerous reports have appeared on lamivudine use for the treatment of hepatitis B virus (HBV) infection after renal transplantation (RT). However, the efficacy and safety of lamivudine after RT remain unclear. Methods. The authors evaluated the efficacy and safety of initial lamivudine monotherapy in RT recipients with hepatitis B by performing a systematic review of the literature with a meta-analysis of clinical trials. The primary outcomes were hepatitis B (HB) e antigen (Ag) and HBV-DNA clearance (as measures of efficacy); the secondary outcomes were biochemical response (as measures of efficacy), dropout rate, and lamivudine resistance (as measures of tolerability). The authors used the random effects model of DerSimonian and Laird, and outcomes were analyzed on an intent-to-treat basis. Results. The authors identified 14 clinical trials (184 patients); all of these were prospective cohort studies. The mean overall estimate for HBV-DNA and HBeAg clearance, alanine aminotransferase normalization, and lamivudine resistance was 91% (95% confidence interval [CI], 86%-96%), 27% (95% CI, 16%-39%), 81% (95% CI, 700%-92%), and 18% (95% CI, 10%-37%), respectively. HBeAg seroconversion rate was assessed in four (28%) trials and ranged between 0% and 46%. The P value was greater than 0.05 for our test of study homogeneity. There was no association between rate of patients who were male patients or had cirrhosis, race, age, lamivudine dose, and HBV-DNA or HBeAg clearance. Increased duration of lamivudine therapy was positively associated with frequency of HBeAg loss (r=0.51, P=0.039) and lamivudine resistance (r=0.620, P=0.019). Only 2 (14%) of 14 studies reported a dropout rate greater than 0%. Conclusions. Our meta-analysis showed that the majority of RT recipients with hepatitis B had high virologic and biochemical response with lamivudine. Tolerance to lamivudine was good. However, lamivudine resistance was frequent with prolonged therapy, potentially limiting its long-term efficacy after RT.

AB - Background. Numerous reports have appeared on lamivudine use for the treatment of hepatitis B virus (HBV) infection after renal transplantation (RT). However, the efficacy and safety of lamivudine after RT remain unclear. Methods. The authors evaluated the efficacy and safety of initial lamivudine monotherapy in RT recipients with hepatitis B by performing a systematic review of the literature with a meta-analysis of clinical trials. The primary outcomes were hepatitis B (HB) e antigen (Ag) and HBV-DNA clearance (as measures of efficacy); the secondary outcomes were biochemical response (as measures of efficacy), dropout rate, and lamivudine resistance (as measures of tolerability). The authors used the random effects model of DerSimonian and Laird, and outcomes were analyzed on an intent-to-treat basis. Results. The authors identified 14 clinical trials (184 patients); all of these were prospective cohort studies. The mean overall estimate for HBV-DNA and HBeAg clearance, alanine aminotransferase normalization, and lamivudine resistance was 91% (95% confidence interval [CI], 86%-96%), 27% (95% CI, 16%-39%), 81% (95% CI, 700%-92%), and 18% (95% CI, 10%-37%), respectively. HBeAg seroconversion rate was assessed in four (28%) trials and ranged between 0% and 46%. The P value was greater than 0.05 for our test of study homogeneity. There was no association between rate of patients who were male patients or had cirrhosis, race, age, lamivudine dose, and HBV-DNA or HBeAg clearance. Increased duration of lamivudine therapy was positively associated with frequency of HBeAg loss (r=0.51, P=0.039) and lamivudine resistance (r=0.620, P=0.019). Only 2 (14%) of 14 studies reported a dropout rate greater than 0%. Conclusions. Our meta-analysis showed that the majority of RT recipients with hepatitis B had high virologic and biochemical response with lamivudine. Tolerance to lamivudine was good. However, lamivudine resistance was frequent with prolonged therapy, potentially limiting its long-term efficacy after RT.

UR - http://www.scopus.com/inward/record.url?scp=1842577541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842577541&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000116448.97841.6D

DO - 10.1097/01.TP.0000116448.97841.6D

M3 - Article

C2 - 15077027

AN - SCOPUS:1842577541

VL - 77

SP - 859

EP - 864

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -